Surrozen, Inc. Common Stock SRZN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-14T01:13:21.673Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T21:00:00.562036752Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-14T01:13:20.882566+00:00
Surrozen, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 24.61 | 300.0% | 28.4% | |||
| 25Δ | 25.85 | 300.0% | 25.6% | |||
| 30Δ | 44.71 | 334.8% | 48.4% | 27.59 | 253.4% | 20.2% |
| 35Δ | 34.41 | 121.4% | 12.6% | 29.33 | 206.8% | 14.9% |
| 40Δ | 33.72 | 118.7% | 11.2% | 30.40 | 181.4% | 12.0% |
| 45Δ | 33.03 | 115.9% | 9.7% | 31.05 | 169.5% | 10.5% |
| 50Δ | 32.34 | 113.2% | 8.3% | 31.70 | 157.5% | 9.1% |
| 55Δ | 31.65 | 110.4% | 6.9% | 32.36 | 145.6% | 7.6% |
| 60Δ | 30.97 | 107.7% | 5.5% | 33.01 | 133.7% | 6.2% |
| 65Δ | 30.28 | 105.0% | 4.0% | 33.66 | 121.8% | 4.7% |
| 70Δ | 34.31 | 109.9% | 3.3% | |||
| 75Δ | 34.96 | 97.9% | 1.9% | |||
| 80Δ | ||||||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 24.61
- IV
- 300.0%
- B/E move
- 28.4%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.85
- IV
- 300.0%
- B/E move
- 25.6%
30Δ
- Pseudo strike
- 44.71
- IV
- 334.8%
- B/E move
- 48.4%
- Pseudo strike
- 27.59
- IV
- 253.4%
- B/E move
- 20.2%
35Δ
- Pseudo strike
- 34.41
- IV
- 121.4%
- B/E move
- 12.6%
- Pseudo strike
- 29.33
- IV
- 206.8%
- B/E move
- 14.9%
40Δ
- Pseudo strike
- 33.72
- IV
- 118.7%
- B/E move
- 11.2%
- Pseudo strike
- 30.40
- IV
- 181.4%
- B/E move
- 12.0%
45Δ
- Pseudo strike
- 33.03
- IV
- 115.9%
- B/E move
- 9.7%
- Pseudo strike
- 31.05
- IV
- 169.5%
- B/E move
- 10.5%
50Δ
- Pseudo strike
- 32.34
- IV
- 113.2%
- B/E move
- 8.3%
- Pseudo strike
- 31.70
- IV
- 157.5%
- B/E move
- 9.1%
55Δ
- Pseudo strike
- 31.65
- IV
- 110.4%
- B/E move
- 6.9%
- Pseudo strike
- 32.36
- IV
- 145.6%
- B/E move
- 7.6%
60Δ
- Pseudo strike
- 30.97
- IV
- 107.7%
- B/E move
- 5.5%
- Pseudo strike
- 33.01
- IV
- 133.7%
- B/E move
- 6.2%
65Δ
- Pseudo strike
- 30.28
- IV
- 105.0%
- B/E move
- 4.0%
- Pseudo strike
- 33.66
- IV
- 121.8%
- B/E move
- 4.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.31
- IV
- 109.9%
- B/E move
- 3.3%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 34.96
- IV
- 97.9%
- B/E move
- 1.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 89.57% | |
| 88.07% | |
| 87.51% | |
| 86.93% | |
| 88.27% | |
| 104.36% | |
| 87.49% | |
| 87.33% | |
| 88.76% | |
| 87.72% |
Biotechnology
STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases…
More →STRO
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
More →STTK
Description unavailable
More →SVRA
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
More →SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Description unavailable
More →